Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer

A method of treatment of a melanoma, or primary or metastatic liver cancer in a human comprising separately administering a therapeutically effective amount of:

• (1) an intralesional chemoablative pharmaceutical composition to elicit ablation of at least one melanoma, or primary or metastatic liver cancerous tumor;
• followed by administration of (2) a therapeutically effective amount of a systemic immunomodulatory anticancer agent that is a systemic enhancer of immune system down-regulation or that is a systemic enhancer of immune system up-regulation in a combination therapeutic regimen,
• wherein said intralesional chemoablative pharmaceutical composition comprises an intralesional (IL) chemoablative agent comprising rose bengal (4,5,6,7-tetrachloro-2′,4′,5′,7′-tetraiodofluorescein) in an appropriate pharmaceutical composition, including a 0.1% (w/v) or higher concentration aqueous solution of rose bengal, or a physiologically acceptable salt of rose bengal, said intralesional chemoablative pharmaceutical composition being administered intralesionally into said at least one melanoma, or primary or metastatic liver cancerous tumor at about 0.1 mL/cc lesion volume to about 2 mL/cc lesion volume.